CNTX

Context Therapeutics Inc. is a biotechnology company operating in the healthcare sector. With a market capitalization of $142.41 million and 12 employees, it is a relatively small player in its industry. The company's financial health reveals significant losses, with net income totaling -$26,440,916 over the trailing twelve months (TTM). The operating margin and profit margin are both at 0.0%, indicating that the company has not generated any profits from operations. Context Therapeutics also reported negative earnings before interest, taxes, depreciation, and amortization (EBITDA) of $-30,193,288 over the same period. The debt-to-equity ratio stands at 0.19, suggesting a relatively manageable level of debt. Context Therapeutics' valuation is characterized by a forward price-to-earnings (P/E) ratio of -3.75 and an enterprise value to earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio of -2.17. The company's gross margin, operating margin, and profit margin are all at 0.0%, indicating no revenue generation from its operations. The return on equity is -$33.7% and the return on assets is -$22.8%.